Introduction and Overview In 1941 Lawrence and Johnson described a “circulating anticoagulant” in a patient with hemophilia who became refractory to blood transfusions for the treatment of bleeding. Over the next several years, they and others determined that this substance…
In this chapter the less common congenital disorders of hemostasis are discussed. These include disorders of fibrinogen, prothrombin, and factors V, VII, X, and XI. (Disorders of factors VIII and IX are discussed in Chapter 3 .) In addition, the…
Epidemiology and Genetics The hemophilias are the best known of the hereditary bleeding disorders. Hemophilia A or B arises as the result of a congenital deficiency of coagulation factor protein VIII or IX, respectively. Both are X-linked recessive disorders, almost…
Introduction In the current medical climate of laboratory expertise and automation, an expanded menu of increasingly sophisticated testing can provide immediately meaningful diagnostic, therapeutic, and prognostic indicators. On the other hand, economic justification and insurance “gatekeeping” often constrain the physician's…
Life is short, and the art long, the occasion fleeting, experience fallacious, and judgment difficult. a Hippocrates (460–370 bc ) is considered to be the founder of European medicine. He lived in Greece during the Classic Period and was a…
Acknowledgments Dr. Cornetta's effort was supported, in part, with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N92019D00018 for the National Gene Vector Biorepository Program.…
Introduction The growing clinical experience with chimeric antigen receptor (CAR) T-cells targeting CD19 has indicated that this therapy can induce remission in a high percentage of relapsed and refractory patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) or B-cell non-Hodgkin's…
Acknowledgment We would like to thank Ms. Catherine Gillespie for the professional editing and proofreading of the chapter. Introduction Central nervous system (CNS) tumors are a diverse group of neoplasms that have been classified by the World Health Organization (WHO)…
Introduction The success of chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma has led to interest in developing CAR T-cell treatments for other malignancies. The modular nature of the CAR brought hope that simply…
Disclaimer The content of this publication does not necessarily reflect the views of policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government. Introduction Treatment…